Study endpoints
hypoxemia, bradycardia, hypotension, pain
ADVERSE EFFECTS, SECONDARY, RESPIRATORY DEPRESSION
The primary endpoint of the study was the attainment rate of the IOC2 target during operation. The secondary endpoints were associated with the composite rate of major adverse effects, including the incidence of hypoxemia (i.e. respiratory depression), haemodynamic changes (i.e. hypotension and bradycardia), EMG activity and IOC1. The patients received instructions for using a 10 cm visual analogue scale (VAS) to assess pain [VAS 0 (no pain) to VAS 10 (the worst possible pain)] once daily postoperatively. The maximum VAS (VAS